Patents by Inventor Adam Bachstetter

Adam Bachstetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES
    Publication number: 20210130429
    Abstract: The subject invention pertains to the use of fractalkine (FKN, CX3CL1) and its receptor CX3CR1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements. In one embodiment, the subject invention is used to treat or ameliorate Parkinson's disease. The present invention can also be used to treat or ameliorate neuroinflammatory and/or neurodegenerative diseases including, but not limited to, Alzheimer's disease, epilepsy, aging, and traumatic brain injury.
    Type: Application
    Filed: October 27, 2020
    Publication date: May 6, 2021
    Inventors: Carmelina GEMMA, Paula C. BICKFORD, Kevin R. NASH, Josh MORGANTI, Adam BACHSTETTER
  • Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
    Patent number: 10815285
    Abstract: The subject invention pertains to the use of fractalkine (FKN, CX3CL1) and its receptor CX3CR1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements. In one embodiment, the subject invention is used to treat or ameliorate Parkinson's disease. The present invention can also be used to treat or ameliorate neuroinflammatory and/or neurodegenerative diseases including, but not limited to, Alzheimer's disease, epilepsy, aging, and traumatic brain injury.
    Type: Grant
    Filed: June 30, 2012
    Date of Patent: October 27, 2020
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Carmelina Gemma, Paula C. Bickford, Kevin R. Nash, Josh Morganti, Adam Bachstetter
  • RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES
    Publication number: 20140205570
    Abstract: The subject invention pertains to the use of fractalkine (FKN, CX3CL1) and its receptor CX3CR1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements. In one embodiment, the subject invention is used to treat or ameliorate Parkinson's disease. The present invention can also be used to treat or ameliorate neuroinflammatory and/or neurodegenerative diseases including, but not limited to, Alzheimer's disease, epilepsy, aging, and traumatic brain injury.
    Type: Application
    Filed: June 30, 2012
    Publication date: July 24, 2014
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Carmelina Gemma, Paula C. Bickford, Kevin R. Nash, Josh Morganti, Adam Bachstetter